贝伐单抗
医学
内科学
肿瘤科
结直肠癌
基因签名
化疗
癌症
基因
基因表达
生物
生物化学
作者
Roberto Moretto,Mirella Giordano,Anello Marcello Poma,Alessandro Passardi,Alessandra Boccaccino,Filippo Pietrantonio,Gianluca Tomasello,Giuseppe Aprile,Sara Lonardi,Veronica Conca,Cristina Granetto,Antonio Frassoldati,Matteo Clavarezza,A. Bertolini,Marco Maria Germani,Clara Ugolini,Gabriella Fontanini,Gianluca Masi,Alfredo Falcone,Chiara Cremolini
标识
DOI:10.1016/j.ejca.2021.04.039
摘要
Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study.Clinical characteristics and gene expression signatures of patients with BRAF-mutant mCRC enrolled in the TRIBE2 study were evaluated with the aim of understanding that patients may derive benefit from the intensification of the upfront chemotherapy.Of 46 BRAF-mutant tumour samples analysed, 24 (52%) and 22 (48%) were classified as BM1 and BM2, respectively, and 27 (59%) and 19 (41%) were assigned to ligand-independent (LI) and ligand-dependent (LD) Wnt pathway subgroups, respectively. No prognostic impact was shown for both BM1/BM2 and LI/LD subtypes. No interaction was evident between BM1/BM2 or LI/LD signatures and the benefit provided by FOLFOXIRI/bevacizumab. Significant interaction effect was evident in terms of progression-free survival between treatment arm and primary tumour sidedness (P = 0.05) and Eastern Cooperative Oncology Group performance status (ECOG-PS; P < 0.001).Gene expression analysis failed to identify patients with BRAF-mutant mCRC candidate to upfront FOLFOXIRI/bevacizumab. ECOG-PS >0 and left-sidedness seem associated with no benefit from the intensified treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI